Dr. Stefan O. Ciurea is a UCI Health hematologist and director of the Hematopoietic Stem Cell Transplantation and Cellular Therapy Program at the Chao Family Comprehensive Cancer Center. and original work. Through participation in clinical trials, patients at UCI Health can gain access to new therapies long before they become available to the general public. As the only academic health system in Orange County, our multifaceted organization is dedicated to the discovery of new medical frontiers, to the teaching of . Research is conducted under the supervision of the research mentor and the research oversight committee. Irvine, Calif., Nov. 12, 2014 Researchers at the UC Irvine School of Medicine have received a $2.04 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases to study genetic modifiers of iron status in hemochromatosis, a hereditary disease in which affected persons suffer excessive dietary iron absorption. Experience being involved in non-cancer therapeutics development in addition to the cancer experience is a plus View Profile . Fellows are expected to develop sufficient research experience by the end of the rotation to be able to prepare papers for presentation at national and regional meetings and manuscripts for publication in peer-reviewed medical journals. in Orange County, which means that patients with leukemia, lymphoma and other cancers no longer need to travel long distances for this life-saving treatment. At the cancer center, you are cared for by a world-class team of cancer specialists, including medical oncologists, surgeons, radiation oncologists and pathologists, as well as highly trained nurses, rehabilitation therapists, pharmacists, social workers and dietitians. We also offer additional services, such as dietary guidance, pain management, counseling and support groups. It also underscores our commitment to cancer prevention research as well as our extensive community outreach and education programs. Phone: (714) 456-7511 Fax: (714) 456-6025 Email: obrien@uci.edu University of California, Irvine 101 The City Drive South Building 23, Room 405 Mail Code: 2675 Orange, CA 92868 Research Interests Hematologic malignancies, both acute and chronic leukemia URL Chao Family Comprehensive Cancer Center Publications Our cancer experts also are available to provide second opinions Welcome to the Division of Hematology/Oncology at UC Irvine's School of Medicine. We are recognized for delivering the highest quality care by the Quality OncologyPractice Initiative (QOPI) CertificationProgram, which is an affiliate of the American Society of Clinical Oncology. Chief, Division of Hematology/Oncology Melanie Funes, PhD Chief Administrative Officer Associate Director, Administration & Finance Senior Leadership Council Allen Chen, MD Professor and Chair, Department of Radiation Oncology Maheswari "Magi" Senthil, MD Medical Director of Oncology Services We are participating in a National Cancer Institute clinical trial to determine whether COVID-19 affects therapies in cancer patients who acquire the virus. Help advance education and research in the Division of Hematology/Oncology through charitable giving. Faculty members in these divisions are involved in a number of research projects. In many cases, this includes chemotherapy following another procedure, such as surgery. If you are not already licensed in the state, contact the Medical Board of California online or at 1426 Howe Ave., Suite 54, Sacramento, CA 95825-3236. Applications should be submitted as early as possible in order to meet ERAS deadlines for supporting documents and interview schedules. Hematology, Internal Medicine, Oncology (0) 54 years exp . Cancer Support and Survivorship Services focuses on treating the whole patient, providing assistance with symptom management, supportive care and survivorship planning. A disability plan is available through the Irvine House Staff Association. . http://www.avensonline.org/fulltextarticles/jun-2380-0585-02-0009.html, Obstructive Jaundice as Initial Presentation of Multiple Myeloma: Case Presentation and Literature Review, https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/26221143/, I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib, https://www.sciencedirect.com/science/article/pii/S0169500215000938?via%3Dihub, Pancytopenia in a patient with cystinosis secondary to myelosuppression from cystine crystal deposition: a case report, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573917/, Patients' preferences for biopsy result notification in an era of electronic messaging methods, https://jamanetwork.com/journals/jamadermatology/fullarticle/2212245, Assessing Bacterial Isolates in Bloodstream Infections and Trend of the Antimicrobial Resistance in the Hematological and Solid Malignancies, http://www.bloodjournal.org/content/126/23/5628/tab-article-info, Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4254519/, Mammalian Y chromosomes retain widely expressed dosage-sensitive regulators, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139287/, The case of the missed physical examination: testicular carcinoma presenting as a GI bleed, http://ascopubs.org/doi/abs/10.1200/JCO.2012.45.2680?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed, Mortality risk after preoperative versus postoperative chemotherapy and radiotherapy in lymph node-positive rectal cancer, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551443/, Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3593948/, Heart rate decrease during crizotinib treatment and potential correlation to clinical response, Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3593561/, Excessive therapeutic response in a case of blastic plasmacytoid dendritic cell neoplasm, Population-based evaluation of adenosquamous carcinoma of the colon and rectum, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3330249/, Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy, https://www.futuremedicine.com/doi/full/10.2217/fon.12.25?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed&, Role of obesity in a randomized placebo-controlled trial of difluoromethylornithine (DFMO) + sulindac for the prevention of sporadic colorectal adenomas, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3443348/, New mechanistic explanation for the localization of ulcers in the rat duodenum: Role of iron and selective uptake of cysteamine, https://www.sciencedirect.com/science/article/pii/S0003986112002135?via%3Dihub, Meat consumption, ornithine decarboxylase gene polymorphism, and outcomes after colorectal cancer diagnosis, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3516190/, Risk of second primary colorectal cancer among colorectal cancer cases: a population-based analysis, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072650/, Timing of radiation therapy, lymph node retrieval, and survival in rectal cancer, https://insights.ovid.com/pubmed?pmid=21471752, Oligohydramnios associated with administration of weekly paclitaxel for triple-negative breast cancer during pregnancy, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202168/, Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140277/, Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017764/, Differentiation of tubular and villous adenomas based on Wnt pathway-related gene expression profiles, https://www.spandidos-publications.com/ijmm/26/1/121, Target of rapamycin signaling in leukemia and lymphoma, http://clincancerres.aacrjournals.org/content/16/22/5374.long, Board-certification or board-eligibility in internal medicine, Proof of medical school graduation (original diploma), Proof of passing the three-step United States Medical Licensing Examination (USMLE), U.S. citizenship, permanent residency, or J-1 visa with ECFMG sponsorship. Universitatea de Medicina si Farmacie Iasi, Fax: These include solid-tumor cancers such as melanoma, colorectal, breast and prostate cancer, as well asmalignancies of the blood, such as leukemia and lymphoma. May 18-22, 2012 15. For questions about the application process, go to ERAS online or call 215.966.3940. Pediatric Hematology-Oncology (5) 41 years exp . Assistant/ Associate/ Full Professor In Residence (Hematology/Oncology) UC Irvine Irvine, CA. For example, radiation or chemotherapy may be used to shrink a tumor before surgery. Rapid Fire Lymphoma and Multiple Myeloma Challenge yourself in your knowledge of lymphomas and multiple myeloma Play Now Rapid Fire Leukemia and Myeloproliferative Neoplasm The Department of Medicine is seeking candidates for an In Residence faculty position in the Division of Hematology/Oncology, at the Assistant Professor level. UCI Health hematologic oncologists provide consultation and treatment for patients with many different types of cancer, These include including malignancies of the blood such as leukemia, lymphoma and myeloma, as well as solid tumor carcinomas such as colon, breast and prostate. Jason A. Zell, DO, MPH, MSDirector, Fellowship Program, Elizabeth Yi, MPH, MBADivision Administrator Email:elizabeth.yi@uci.edu, Elizabeth AndersonAcademic Programs AnalystEmail: elizabeth.anderson@uci.edu, Christopher G. HaymondBusiness Support Assistant AnalystEmail:chaymond@uci.edu, Elizabeth PearsonClinical Programs Assistant Analyst & Administrative Assistant to Division ChiefEmail: epearson@uci.edu, Christopher SongEducation Programs Assistant AnalystEmail:csong3@uci.edu, University of California, Irvine Irvine, CA 92697. Our patients receive the best possible care because, as a comprehensive cancer center, we: Our multidisciplinary team of world-class oncologists, surgeons, radiation oncologists, pathologists, nurses, rehabilitation therapists, pharmacists, social workers and dietitians works together seamlessly to treat cancers of all types and degrees of severity. Our physicians participate in National Cancer Institute-sponsored clinical trials featuring new drugs and the most advanced options in treatment and care. Candidates must be a U.S. citizen, permanent resident orhold a J-1 visa with ECFMG sponsorshipat the time of application submission. Use MyChart to schedule appointments, request prescription renewals, send messages to your care team and more. During and after treatment, our cancer center dietitians, social workers and rehabilitation therapists work closely with you to support your recovery. Cancer patients at UCI Health benefit from an individualized treatment plan tailored to their specific condition. Diversity is core to our ability to offer compassionate and culturally competent care in a variety of practice settings, to patients from all walks of life, addressing simple to complex healthcare needs, while working with others who embrace a broad variety of backgrounds, experience, and perspectives. Internal Medicine, Oncology (5) 22 years exp . He completed an internal medicine residency at UPMC Pinnacle Harrisburg in Harrisburg, Pa. We have one of the largest early-phase clinical research programs in Southern California, giving patients access to promising experimental medicines in the very earliest studies. Humphrey Bogart Cause Of Death, Articles U